European Patent Office to Grant SporeGen’s Patent Application for THY-X-CISE® Technology

• September 25, 2023
• SporeGen

SporeGen® announces update from research collaboration under Innovate UK grant award to develop a biotherapeutic treatment (SPOR-COV®) for COVID-19 and Influenza

• May 08, 2023
• SporeGen

SporeGen® Announces Collaboration with Destiny Pharma Supported by an Innovate UK grant award to Co-develop Novel, Preventative Treatment for COVID-19

• September 08, 2020
• SporeGen

· SPOR-COV^TM prophylactic approach targets the innate immune system with potential to develop COVID-19 protection within a few days of treatment

· Innovate UK grant of £800,000 to support SPOR-COV programme over the next 18 months

TRANSVAC Funding of SPORCOVAX, SporeGen's Mucosal Vaccine to COVID-19

• September 14, 2021
• SporeGen

SporeGen® receives GRAS Notice No. GRN 000905 from the FDA for its probiotic SG188

• June 10, 2020
• SporeGen
• Latest News